BioSpace News Archive

Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16.

Pain, fluids, odor—and endless dressing changes: Chronic wounds often fail to close, and patients’ bodies appear unable to heal.

AstraZeneca recently reported positive interim data from clinical trials of two, and potentially a third, of its drugs for cancer.

During the first presidential debate of Democratic candidates vying for that party’s presidential nomination, it didn’t take long for the pharma industry to take center stage.

Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.

Cambridge, Mass.-based Vaxess Technologies is inching closer to developing a bandage-like product that will be able to administer vaccines and other therapeutics through the skin.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces a pre-close trading update for the 12 months ended 30 June 2019 and the successful outcome of the litigation related to the Grass MATA MPL Phase II trial.

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

Sartorius Stedim Biotech (SSB) launched a new vessel for its ambr® 250 modularbenchtop automated mini bioreactor system.